Načítá se...
Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo
Agonistic anti-TNF receptor (TNFR) superfamily member antibodies are a class of promising antitumor therapies in active clinical investigation. An unexpected requirement for inhibitory Fcγ receptor FcγRIIB coengagement has recently been described for their in vivo antitumor activities. Although thes...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
National Academy of Sciences
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3845179/ https://ncbi.nlm.nih.gov/pubmed/24218606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1319502110 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|